-
Boehringer Ingelheim and Eli Lilly’s Jardiance Wins FDA Approval for CKD Prevention
•
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have received regulatory approval from the US Food and Drug Administration (FDA) for their SGLT2 inhibitor, Jardiance (empagliflozin), marking a significant advancement in the treatment of chronic kidney disease (CKD). The drug is now approved for the prevention of kidney function decline,…
-
MSD’s Keytruda Meets Endpoints in Urothelial Carcinoma Trial but Misses in NSCLC Study
•
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading global pharmaceutical company, last week released clinical data from separate late-stage studies for its anti-PD-1 biologic, Keytruda (pembrolizumab), in combination with other oncology therapies from different partners. The results presented a mixed picture of success and challenges in the field of…
-
Betta Pharmaceuticals’ CFT8919 Accepted for Review by China’s NMPA for EGFR L858R Solid Tumors
•
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a China-based pharmaceutical company, has announced that the National Medical Products Administration (NMPA) in China has accepted a clinical trial filing for its Category 1 drug candidate, CFT8919. This development marks a significant step forward in the drug’s journey towards clinical evaluation and potential…
-
Simcere Pharmaceutical Reports 25.2% Revenue Growth in 2023 Interim Financials
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has released its interim financial report for 2023, revealing a robust performance in the first half of the year. The company reported revenues of RMB 3.379 billion (USD 466 million), reflecting a 25.2% year-on-year (YOY) increase. Notably, sales of innovative drugs accounted for 71%…
-
3D Medicines’ H1 2023 Report Highlights 70.3% YOY Growth in Envafolimab Sales
•
China-based oncology specialist 3D Medicines (HKG: 1244) has released its financial report for the first half of 2023, highlighting significant revenue generated by envafolimab, a programmed death-ligand 1 (PD-L1) antibody capable of subcutaneous injection. The product has been covered under 32 city-level insurance schemes (HuiMinBao) and has seen rapid uptake,…
-
Acotec Scientific Holdings Receives Japanese Marketing Approval for Peripheral Support Catheter Vericor
•
Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it has received marketing approval from the Ministry of Health, Labour and Welfare of Japan for its peripheral support catheter, Vericor. This approval allows the product to be used in conjunction with a guide wire to…
-
Chime Biologics Partners with Panolos Bioscience to Speed Up Multi-Specific Protein Development
•
China-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics Ltd has announced a strategic cooperation with South Korean biotech firm Panolos Bioscience. The partnership aims to accelerate the development of multi-specific proteins, although no financial details have been disclosed. Focus on Multi-Specific TherapeuticsPanolos Bioscience is a biopharmaceutical company specializing in…
-
Hangzhou Qihan Biotechnology Secures Over $13.8 Million in Pre-Series B Financing
•
Hangzhou Qihan Biotechnology Co., Ltd, a leading xenotransplantation specialist based in China, has reportedly raised over RMB 100 million (USD 13.8 million) in a pre-Series B financing round. The funds will be allocated to support product iteration and global development initiatives over the next four years, marking a significant step…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
